Dr Reddys Laboratories Stock Revenue
RDY Stock | USD 73.35 1.04 1.44% |
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDY Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
At this time, Dr Reddys' Total Revenue is fairly stable compared to the past year. Ebit Per Revenue is likely to rise to 0.37 in 2024, whereas Current Deferred Revenue is likely to drop slightly above 1.7 B in 2024. RDY | Revenue |
RDY Revenue Analysis
Dr Reddys' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
More About Revenue | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 41.6B | 48.9B | 56.2B | 59.0B | Total Assets | 296.7B | 322.9B | 371.3B | 206.1B |
Revenue | = | Money Received | - | Discounts and Returns |
Current Dr Reddys Revenue | 245.88 B |
Most of Dr Reddys' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of RDY
Projected quarterly revenue analysis of Dr Reddys Laboratories provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Dr Reddys match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Dr Reddys' stock price.
RDY Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Dr Reddys is extremely important. It helps to project a fair market value of RDY Stock properly, considering its historical fundamentals such as Revenue. Since Dr Reddys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dr Reddys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dr Reddys' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition |
RDY Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Dr Reddys Laboratories reported 245.88 B of revenue. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is significantly lower than that of the firm.
RDY Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in revenue category among related companies.
Dr Reddys Institutional Holders
Institutional Holdings refers to the ownership stake in Dr Reddys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dr Reddys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dr Reddys' value.Shares | Gqg Partners Llc | 2023-12-31 | 437 K | Ameriprise Financial Inc | 2023-09-30 | 434.5 K | Millennium Management Llc | 2023-09-30 | 361.6 K | Grantham, Mayo, Van Otterloo & Co., Llc | 2023-12-31 | 329.1 K | Lazard Asset Management Llc | 2023-09-30 | 306.1 K | Acadian Asset Management Llc | 2023-09-30 | 270.3 K | Schroder Investment Management Group | 2023-12-31 | 266.7 K | Mondrian Investment Partners Ltd | 2023-09-30 | 216.1 K | Assenagon Asset Management Sa | 2023-12-31 | 196.1 K | Blackrock Inc | 2023-12-31 | 3 M | Royal Bank Of Canada | 2023-09-30 | 2.1 M |
RDY Fundamentals
Return On Equity | 0.21 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.19 % | ||||
Operating Margin | 0.25 % | ||||
Current Valuation | 11.45 B | ||||
Shares Outstanding | 166.52 M | ||||
Shares Owned By Institutions | 14.97 % | ||||
Number Of Shares Shorted | 709.29 K | ||||
Price To Earning | 31.58 X | ||||
Price To Book | 3.75 X | ||||
Price To Sales | 0.05 X | ||||
Revenue | 245.88 B | ||||
Gross Profit | 113.84 B | ||||
EBITDA | 108.78 B | ||||
Net Income | 60.48 B | ||||
Cash And Equivalents | 2.93 B | ||||
Cash Per Share | 208.58 X | ||||
Total Debt | 13.47 B | ||||
Debt To Equity | 0.12 % | ||||
Current Ratio | 1.98 X | ||||
Book Value Per Share | 1,609 X | ||||
Cash Flow From Operations | 58.87 B | ||||
Short Ratio | 2.90 X | ||||
Earnings Per Share | 3.75 X | ||||
Price To Earnings To Growth | 4.77 X | ||||
Target Price | 78.13 | ||||
Number Of Employees | 25.86 K | ||||
Beta | 0.35 | ||||
Market Capitalization | 12.29 B | ||||
Total Asset | 322.85 B | ||||
Retained Earnings | 215.59 B | ||||
Working Capital | 118.53 B | ||||
Current Asset | 1.81 B | ||||
Current Liabilities | 976 M | ||||
Z Score | 3.8 | ||||
Annual Yield | 0.01 % | ||||
Five Year Return | 0.72 % | ||||
Net Asset | 322.85 B | ||||
Last Dividend Paid | 40.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Current Deferred Revenue | 1.8 B | 1.7 B | |
Total Revenue | 282.8 B | 296.9 B | |
Cost Of Revenue | 49.3 B | 44.3 B | |
Ebit Per Revenue | 0.35 | 0.37 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dr Reddys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dr Reddys' short interest history, or implied volatility extrapolated from Dr Reddys options trading.
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Dr Reddys Piotroski F Score and Dr Reddys Altman Z Score analysis. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.75 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.